Advertisement

O.C. BUSINESS PLUS | ORANGE COUNTY EARNINGS

NeoTherapeutics Inc.

November 04, 2000

The Irvine biopharmaceutical incurred a third-quarter net loss of $13.2 million, or $1.27 a share, which included a noncash charge of $1 million from the sale of convertible preferred stock of its NeoGene unit. The net loss for the same period last year was $5.3 million, or 70 cents a share. Revenue was not reported.

Advertisement
Los Angeles Times Articles
|
|
|